keyword
MENU ▼
Read by QxMD icon Read
search

Diabetic macular edema

keyword
https://www.readbyqxmd.com/read/28748377/microvascular-effects-of-glucagon-like-peptide-1-receptor-agonists-in-type-2-diabetes-a-meta-analysis-of-randomized-controlled-trials
#1
Ilaria Dicembrini, Besmir Nreu, Alessia Scatena, Francesco Andreozzi, Giorgio Sesti, Edoardo Mannucci, Matteo Monami
AIMS: Results with GLP1-receptor agonists (GLP-1RA) on microvascular complications of diabetes are contrasting. In trials designed for cardiovascular outcomes, both liraglutide and semaglutide were associated with a relevant reduction in the incidence and progression of nephropathy. On the other hand, in the same trials, semaglutide was associated with an increased progression of retinopathy, and a similar trend was observed for liraglutide. This meta-analysis is aimed at assessing the effects of GLP-1RA on retinopathy and nephropathy...
July 27, 2017: Acta Diabetologica
https://www.readbyqxmd.com/read/28740734/effect-of-topical-nepafenac-on-central-foveal-thickness-following-panretinal-photocoagulation-in-diabetic-patients
#2
Nahla B Abu Hussein, Ahmed A Mohalhal, Dalia A Ghalwash, Ahmed A Abdel-Kader
PURPOSE: To evaluate effectiveness of topical nepafenac in reducing macular edema following panretinal photocoagulation (PRP). DESIGN: Prospective randomized double-blinded controlled study. METHODS: Sixty eyes of 60 patients having proliferative or severe nonproliferative diabetic retinopathy had PRP. Patients were then divided into two groups: nepafenac group (30 eyes) receiving 1% topical nepafenac eye drops for 6 months and control group (30 eyes) receiving carboxymethylcellulose eye drops for 6 months...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28731494/subthreshold-micropulse-laser-reduces-anti-vegf-injection-burden-in-patients-with-diabetic-macular-edema
#3
Elad Moisseiev, Sam Abbassi, Sumeer Thinda, Joseph Yoon, Glenn Yiu, Lawrence S Morse
PURPOSE: To evaluate the efficacy of micropulse laser in the early treatment of diabetic macular edema (DME) and its associated burden of anti-vascular endothelial growth factor (VEGF) injections. METHODS: This retrospective comparative study compared a group of 19 eyes with DME treated with micropulse laser to a matched control group of 19 eyes with DME treated with ranibizumab injections without micropulse laser. Recorded parameters included previous medical and ocular history, previous and subsequent ranibizumab injections administered for DME, visual acuity (VA), central macular thickness throughout the follow-up period, and the occurrence of any complications...
July 20, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28730118/efficiency-and-safety-of-laser-photocoagulation-with-or-without-intravitreal-ranibizumab-for-treatment-of-diabetic-macular-edema-a-systematic-review-and-meta-analysis
#4
Tian-Wei Qian, Meng-Ya Zhao, Xin-Xin Li, Xun Xu
AIM: To compare the therapeutic effect and safety of laser photocoagulation along with intravitreal ranibizumab (IVR) versus laser therapy in treatment of diabetic macular edema (DME). METHODS: Pertinent publications were identified through comprehensive searches of PubMed, EMBASE, Web of Science, Cochrane Library, and ClinicalTrials.gov to identify randomized clinical trials (RCTs) comparing IVR+laser to laser monotherapy in patients with DME. Therapeutic effect estimates were determined by weighted mean differences (WMD) of change from baseline in best corrected visual acuity (BCVA) and central retinal thickness (CRT) at 6, 12, or 24mo after initial treatment, and the risk ratios (RR) for the proportions of patients with at least 10 letters of improvement or reduction at 12mo...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28730115/diabetic-macular-edema-in-proliferative-stage-treated-with-anti-vascular-endothelial-growth-factor-agent-and-triamcinolone-acetonide-by-laser-based-strategies
#5
Gang Qiao, Wan-Jiang Dong, Yan Dai, Zhen-Hua Jiang, Hai-Ke Guo
AIM: To appraise the effect of treatment for diabetic macular edema (DME) in proliferative stage with sufficient panrentinal photocoagulation (PRP) therapy and intravitreal injections (IV) Conbercept and posterior subtenon's triamcinolone acetonide (STTA) sequential therapy. METHODS: This prospective clinical randomized controlled trial of cross-over design was conducted in three phases. The participants included cases of DME in proliferative stage. They were divided into two groups and treated with PRP before enrollment...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28730087/frequency-of-diabetic-retinopathy-and-associated-risk-factors-in-khartoum-sudan-population-based-study
#6
Einas S Elwali, Ahmed O Almobarak, Mona A Hassan, Amir A Mahmooud, Heitham Awadalla, Mohamed H Ahmed
AIM: To assess the frequency and associated risk factors of diabetic retinopathy among Sudanese individuals with diabetes attending Makka Eye complex in Khartoum, Sudan. METHODS: The cross sectional hospital based study recruited 316 individuals with diabetes from Makkah Eye Complex Retina Clinic. Standard questionnaire was used to collect demographic data, medical history and life style characteristics. Blood samples were taken to measure HbA1c and lipid profile...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28728160/structural-changes-of-the-macula-on-optical-coherence-tomography-after-vitrectomy-for-proliferative-diabetic-retinopathy
#7
Jong Chan Im, Jong Ho Kim, Dong Ho Park, Jae Pil Shin
PURPOSE: This study aimed to evaluate the relationship between macular structural changes and visual prognosis after pars plana vitrectomy (PPV) for proliferative diabetic retinopathy. METHODS: The study included 60 eyes that had undergone PPV. Macular optical coherence tomography (OCT) findings were classified into 5 groups preoperatively and 10 groups postoperatively. Best-corrected visual acuity (BCVA) were analyzed according to pre- and postoperative OCT. RESULTS: From the preoperative OCT, normal fovea with/without traction, normal fovea with preretinal hemorrhage, and tractional retinal detachment involving fovea showed an increase in BCVA after PPV (all p < 0...
July 21, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28724830/drug-resistant-coagulase-negative-staphylococcal-endophthalmitis-following-dexamethasone-intravitreal-implant
#8
Prabhushanker Mahalingam, Tasneem Tameem Topiwalla, Geetha Ganesan
A 60-year-old female came to our hospital with defective vision due to persistent diabetic macular edema and was treated with intravitreal ozurdex implant in the right eye. Three days later, the patient presented with diminution of vision, ocular pain, congestion, and hypopyon with no fundus view. B-scan ultrasonography showed vitritis, and diagnosis of endophthalmitis was made. Subsequently, 25-gauge pars plana vitrectomy was performed along with intravitreal vancomycin and amikacin and removal of implant...
July 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/28724817/real-world-evidence-of-safety-profile-of-intravitreal-bevacizumab-avastin-in-an-indian-scenario
#9
Prashant Jain, Jay Sheth, Giridhar Anantharaman, Mahesh Gopalakrishnan
PURPOSE: The purpose of this study was to evaluate the safety profile of intravitreal bevacizumab (Avastin) as an off-label pharmacotherapeutic agent for various ocular conditions. METHODS: Retrospective analysis was carried out on 3806 injections of 1761 patients that were administered with intravitreal bevacizumab injection at a tertiary eye care center in India. The injections were administered on a pro re nata basis for various indications such as age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO)...
July 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/28724805/diabetic-retinopathy-current-understanding-mechanisms-and-treatment-strategies
#10
REVIEW
Elia J Duh, Jennifer K Sun, Alan W Stitt
Diabetic retinopathy (DR) causes significant visual loss on a global scale. Treatments for the vision-threatening complications of diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) have greatly improved over the past decade. However, additional therapeutic options are needed that take into account pathology associated with vascular, glial, and neuronal components of the diabetic retina. Recent work indicates that diabetes markedly impacts the retinal neurovascular unit and its interdependent vascular, neuronal, glial, and immune cells...
July 20, 2017: JCI Insight
https://www.readbyqxmd.com/read/28724746/therapeutic-targeting-tumor-progression-locus-2-tpl2-activating-transcription-factor-4-atf4-chemokine-stromal-cell-derived-factor-%C3%AE-sdf1%C3%AE-axis-suppresses-diabetic-retinopathy
#11
De-Wei Lai, Keng-Hung Lin, Wayne Huey-Herng Sheu, Maw-Rong Lee, Chung-Yu Chen, Wen-Jane Lee, Yi-Wen Hung, Chin-Chang Shen, Tsung-Ju Chung, Shing-Hwa Liu, Meei-Ling Sheu
Rationale: Diabetic retinopathy is characterized by vasopermeability, vascular leakage, inflammation, blood-retinal barrier breakdown, capillary degeneration and neovascularization. However, the mechanisms underlying the association between diabetes and progression retinopathy remain unclear. Objective: Tumor progression locus 2 (TPL2), a serine-threonine protein kinase, exerts a pathological effect on vascular angiogenesis. This study investigated the role of N(ε)-(carboxymethyl)lysine (CML), a major advanced glycation end products, and the involved TPL2-related molecular signals in diabetic retinopathy using models of in vitro and in vivo and human samples...
July 19, 2017: Circulation Research
https://www.readbyqxmd.com/read/28724696/is-leukostasis-a-crucial-step-or-epiphenomenon-in-the-pathogenesis-of-diabetic-retinopathy
#12
REVIEW
Anne-Eva van der Wijk, John M Hughes, Ingeborg Klaassen, Cornelis J F Van Noorden, Reinier O Schlingemann
Leukostasis in the retinal microvasculature in animal model studies of diabetes is associated with the development of diabetes-like retinopathy. Therefore, it is generally assumed that adhesion of leukocytes is a central event inciting a chronic, low-grade form of inflammation that causes the vascular abnormalities that are specific for the early stages of diabetic retinopathy (DR), which culminate in diabetic macular edema, proliferative DR, and vision loss in humans. Here, we review the literature critically with respect to leukostasis and assess its pathologic consequences in the human diabetic retina...
July 19, 2017: Journal of Leukocyte Biology
https://www.readbyqxmd.com/read/28719888/inhibition-of-single-routes-of-intracellular-signaling-is-not-sufficient-to-neutralize-the-biphasic-disturbance-of-a-retinal-endothelial-cell-barrier-induced-by-vegf-a165
#13
Heidrun L Deissler, Gerhard K Lang, Gabriele E Lang
BACKGROUND/AIMS: Hallmark of diabetic macular edema is the enhanced permeability of retinal endothelial cells (REC) induced by vascular endothelial growth factor (VEGF-A165), which acts through activating specific receptors. To improve the predictability of inhibitors' potentials to block harmful effects of VEGF-A165, we investigated if its signaling pathways triggered in REC are redundant. METHODS: Immortalized bovine REC monolayers were treated with inhibitors specific for various protein kinases in combination with VEGF-A165...
July 18, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28717786/setting-priorities-for-diabetic-retinopathy-clinical-research-and-identifying-evidence-gaps
#14
Jimmy T Le, Susan Hutfless, Tianjing Li, Neil M Bressler, James Heyward, Ava K Bittner, Adam Glassman, Kay Dickersin
PURPOSE: Prioritizing comparative effectiveness research may contribute to obtaining answers that clinicians perceive they need and may minimize research that could be considered wasteful. Our objective was to identify evidence gaps and set priorities for new systematic reviews and randomized controlled trials for managing diabetic retinopathy (DR), including diabetic macular edema (DME). DESIGN: Cross-sectional study. PARTICIPANTS: Diabetic Retinopathy Clinical Research Network (DRCR...
March 2017: Ophthalmology retina
https://www.readbyqxmd.com/read/28715811/early-response-to-ranibizumab-is-associated-with-12-month-outcome-in-diabetic-macular-edema-after-prior-macular-laser-therapy
#15
Shwu-Jiuan Sheu, Ying-Yen Lee
PURPOSE: To evaluate the efficacy of ranibizumab in persistent or recurrent diabetic macular edema (DME) after previous laser therapy. METHODS: This prospective, interventional study consisted of a 3-month period of scheduled ranibizumab treatment followed by a 9-month period of pro re nata treatment. RESULTS: A total of 21 eyes (18 patients) were included. Both best corrected visual acuity and central retinal thickness had statistically significantly improved from baseline at month 12 (p < 0...
July 18, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28715583/tnf%C3%AE-induced-disruption-of-the-blood-retinal-barrier-in-vitro-is-regulated-by-intracellular-3-5-cyclic-adenosine-monophosphate-levels
#16
Anne-Eva van der Wijk, Ilse M C Vogels, Cornelis J F van Noorden, Ingeborg Klaassen, Reinier O Schlingemann
Purpose: Proinflammatory cytokines such as tumor necrosis factor (TNFα) may have a causative role in blood-retinal barrier (BRB) disruption, which is an essential step in the development of diabetic macular edema. The purpose of our study was to determine whether TNFα increases permeability in an in vitro model of the BRB and to explore the mechanisms involved. Methods: Primary bovine retinal endothelial cells (BRECs) were grown on Transwell inserts and cells were stimulated with TNFα or a combination of TNFα, IL1β, and VEGF...
July 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28712629/the-prime-diabetes-model-novel-methods-for-estimating-long-term-clinical-and-cost-outcomes-in-type-1-diabetes-mellitus
#17
William J Valentine, Richard F Pollock, Rhodri Saunders, Jay Bae, Kirsi Norrbacka, Kristina Boye
BACKGROUND: Recent publications describing long-term follow-up from landmark trials and diabetes registries represent an opportunity to revisit modeling options in type 1 diabetes mellitus (T1DM). OBJECTIVES: To develop a new product-independent model capable of predicting long-term clinical and cost outcomes. METHODS: After a systematic literature review to identify clinical trial and registry data, a model was developed (the PRIME Diabetes Model) to simulate T1DM progression and complication onset...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28708221/rapid-response-to-dexamethasone-intravitreal-implant-in-diabetic-macular-edema
#18
Giuseppe Lo Giudice, Antonio Avarello, Gianluca Campana, Alessandro Galan
PURPOSE: To evaluate the early effects of dexamethasone (DEX) intravitreal implants in patients with diabetic macular edema (DME). METHODS: This was a prospective, single-arm, interventional clinical series. Eighteen patients (18 eyes) with chronic/recalcitrant or naive DME were included. Patients underwent single DEX intravitreal implant. Clinical assessments, including ophthalmologic examination, central retinal thickness (CRT) measurement by spectral-domain optical coherence tomography (SD-OCT) scan, best-corrected visual acuity (BCVA), and intraocular pressure (IOP) were carried out at baseline, 1-3 hours, and then 3, 7, and 30 days after treatment...
July 1, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28704825/dexamethasone-implants-in-diabetic-macular-edema-patients-with-high-visual-acuity
#19
Riccardo Sacconi, Maurizio Battaglia Parodi, Stefano Casati, Rosangela Lattanzio, Giorgio Marchini, Francesco Bandello
PURPOSE: To evaluate the effects of intravitreal dexamethasone (DEX) implants in patients affected by diabetic macular edema (DME) with high best-corrected visual acuity (BCVA) and contraindications to therapy with anti-vascular endothelial growth factor over a 12-month follow-up. METHODS: In this interventional nonrandomized clinical study, 14 consecutive patients (14 eyes) affected by DME with a BCVA of 0.3 LogMAR or better were prospectively enrolled. All patients were treated with a sustained-release 700-μg DEX implant at baseline, revaluated every 6 weeks, and retreated on a pro re nata basis...
July 14, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28700419/planned-foveal-detachment-technique-for-the-resolution-of-diabetic-macular-edema-resistant-to-anti-vascular-endothelial-growth-factor-therapy
#20
Shinji Toshima, Yuki Morizane, Shuhei Kimura, Fumio Shiraga
No abstract text is available yet for this article.
July 11, 2017: Retina
keyword
keyword
8162
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"